DXR Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -3.2%, SMA50 -8.1%, SMA200 5.94%). The stock’s 14-day RSI is 40.53 (neutral), while the ATR of 0.48 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.03% below its high and over 69.5% above its low. Average 10-day trading volume of 4.08 thousand shares is below the 3-month average of 10.29 thousand, indicating normal recent market interest.

Daxor Corporation has 4.98 million shares outstanding. The public float is 2.16 million shares, elevated short interest at 1.80% of float. This equals 38.25 thousand shares. The short ratio is 0.56 days. Institutional investors hold 4.63% of the float. Insiders own 56.64%. FELDSCHUH JOSEPH holds 2.77 million shares, Feldschuh Michael Richard has 213.69 thousand shares and Feldschuh Jonathan Adam has 53.91 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Daxor Corporation (NASDAQ:DXR) closed at $10.95 USD, gaining $0.70 (6.83%) from the previous close of $10.25. The stock is currently mid-range between its 52-week high and low $7.10 and $14.76. With a market capitalization of about $55.17 million, Daxor Corporation is classified as a micro-cap and shows lower-than-market volatility (beta ~0.14). Key stats such as the average daily volume over the past year has been around 10.08 thousand shares, volume is running light vs its 52-week average. Headquartered in Oak Ridge, TN, Daxor Corporation operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Michael Richard Feldschuh, the company employs approximately 37 people and listed since July 25, 1983. Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing.

Daxor Corporation trades at a P/E ratio of 6.0, slightly below the S&P 500 average, with a price-to-sales ratio of 364.66 and a price-to-book ratio of 1.2 suggesting the stock is closer to book value. The P/FCF stands at 323.0, also above market averages.

Daxor Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.02. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Daxor Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.46%, with price expected at $10.90 by May 07, 2026, within a range of $10.49 to $11.32 3-Month Outlook: Projected fall of -24.11%, reaching $8.31 by July 22, 2026, with a range of $7.64 to $8.82. 1-Year Outlook: Projected gain of 126.94%, with price at $24.85 by April 23, 2027, within a range of $17.34 to $35.54.

Daxor Corporation (NASDAQ:DXR) shares are flat -8.68% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Daxor Corporation trading at a premium to the broader market with a P/E of 6.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $22.50, suggesting 105.48% upside. Our AI forecast model points to short-term weakness (-0.46% over two weeks), a medium-term fall (-24.11% over three months), and a longer-term gain (126.94% over one year), with expected trading ranges indicating moderate volatility.